Related Experiment Video
Updated: Dec 25, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Advanced case of PKDL due to delayed treatment: A rare case report
Roshan Kamal Topno1, Vidya Nand Rabi Das2, Maneesh Kumar3
1Department of Epidemiology, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India.
Abstract:
Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clinical isolates of Leishmania donovani has been reported and is one of the major concerns in the treatment of PKDL. Here, we report a highly ulcerated PKDL case that was successfully cured after miltefosine treatment.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Acute Pyelonephritis I: Introduction
Chronic Kidney Disease III: Interprofessional Care

